Non Alcoholic Fatty Liver Disease (NAFLD) Market Size, Share - Growth Analysis Report and Forecast Trends (2026-2035)

Non Alcoholic Fatty Liver Disease (NAFLD) Market Overview

Non alcoholic fatty liver disease (NAFLD) is emerging as a significant chronic liver condition gaining increasing clinical attention worldwide due to rising metabolic risk factors, lifestyle changes, and growing burden of obesity-related complications across populations. The market was valued at USD 17.57 Billion in 2025, and is expected to grow at a steady state, driven by increasing prevalence of metabolic syndrome, improved diagnostic awareness, and rising demand for advanced therapeutic approaches across developed and emerging economies. The ongoing research and pipeline developments are expected to strengthen clinical outcomes and expand treatment accessibility globally and improve patient care delivery worldwide in a sustainable manner.

Non Alcoholic Fatty Liver Disease (NAFLD) Market Growth Analysis and Key Influencers

Non Alcoholic Fatty Liver Disease (NAFLD) Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Non Alcoholic Fatty Liver Disease (NAFLD) Market Growth Drivers

Non Alcoholic Fatty Liver Disease Market Growth Driven by Rising Prevalence and Diagnostic Awareness

The increasing prevalence of the disease, driven by sedentary lifestyles and metabolic disorders, is a key factor driving the growth in the market, as it intensifies the demand for early diagnosis and effective therapeutic interventions. According to Prajakta Ankur Vagurmekar et al., 2024, the prevalence of NAFLD in India ranges from 9% to 53%, while a study in Goa highlights limited clinical attention and the need to assess associated risk factors in adults aged above 30 years in urban communities. This rising burden and underdiagnosis are accelerating screening initiatives and expanding treatment uptake.

Non Alcoholic Fatty Liver Disease (NAFLD) Market Restraints

High Economic Burden and Disease Progression Costs Restrict Market Expansion

The market is significantly constrained by the high economic burden associated with disease progression, comorbidities, and advanced treatment requirements, which limit patient access and healthcare affordability. According to Zobair M. Younossi et al., NAFLD and non-alcoholic steatohepatitis (NASH) impose a substantial financial burden, with lifetime costs of NASH in the United States estimated at USD 223 billion. Additionally, NAFLD in patients with type 2 diabetes may lead to a USD 55.8 billion 20-year cost, along with 65,000 liver transplants, 1.37 million cardiovascular-related deaths, and 812,000 liver-related deaths, further intensifying healthcare expenditure and limiting overall market expansion.

Non Alcoholic Fatty Liver Disease (NAFLD) Market Opportunities

Rising Burden of NAFLD/MASLD Can Create Significant Opportunities for the Market

The increasing nonalcoholic fatty liver disease (NAFLD) epidemiology, now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is expected to create substantial growth opportunities for the market. The growing patient population is accelerating demand for advanced diagnostics, targeted therapeutics, and disease management solutions. For instance, in March 2026, the American Liver Foundation highlighted an AHRQ report showing an 88.1% increase in NAFLD-related inpatient stays between 2016 and 2022 in the United States. The report also estimated that nearly 1 in 4 Americans are affected by MASLD, emphasizing the strong future potential for innovative treatment development and healthcare expansion.

Non Alcoholic Fatty Liver Disease (NAFLD) Market Trends

The market is witnessing several trends including advanced dual agonist therapies and fibrosis-targeted treatment innovations.

Rising Development of Dual Agonist Therapies is Likely to Enhance Market Growth

The growing focus on dual agonist therapies for managing fibrosis and metabolic dysfunction is emerging as a significant trend in the market. These therapies are gaining attention for their potential to simultaneously address liver inflammation, fibrosis progression, obesity, and metabolic complications associated with NAFLD and MASH. For instance, in June 2024, Boehringer Ingelheim announced that survodutide demonstrated substantial fibrosis improvement without worsening MASH in Phase II clinical trials, with up to 64.5% of patients with F2 and F3 fibrosis achieving positive outcomes. The advancement of such next-generation therapies is expected to accelerate treatment adoption and contribute significantly to overall market growth.

Non Alcoholic Fatty Liver Disease (NAFLD) Market Share

FXR Receptor Agonists Expected to Lead the Market Share by Drug Class

The market is segmented by drug class into antioxidants, lipid-lowering agents, thiazolidinediones (TZDs), FXR receptor agonists, fibrosis treatment agents, biguanides, and others. Among these, FXR receptor agonists are expected to lead the market due to their strong potential in addressing liver fibrosis and improving metabolic function, which are critical factors in disease progression. The growing clinical success and regulatory advancements are further strengthening this segment’s position. For instance, in August 2025, Madrigal Pharmaceuticals received European Commission approval for Rezdiffra™ (resmetirom), supported by Phase 3 MAESTRO-NASH trial results demonstrating fibrosis reduction and disease resolution in patients with moderate to advanced fibrosis. This milestone is anticipated to accelerate innovation and therapeutic adoption across the market.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Non Alcoholic Fatty Liver Disease (NAFLD) Market Analysis by Region

The regions included in the report are the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to lead the market due to the high prevalence of obesity, diabetes, and sedentary lifestyles, along with advanced healthcare infrastructure and increasing adoption of innovative diagnostic and treatment approaches. The growing burden of metabolic disorders and obesity continues to contribute significantly to the rising incidence of liver diseases, thereby supporting the growth of the market across major developed and emerging economies.

Leading Players in the Non Alcoholic Fatty Liver Disease (NAFLD) Market

Non Alcoholic Fatty Liver Disease (NAFLD) Market Segmentation

Key Questions Answered in the Non Alcoholic Fatty Liver Disease (NAFLD) Market Report

• What was the non alcoholic fatty liver disease (NAFLD) market value in 2025?
• What is the non alcoholic fatty liver disease (NAFLD) market forecast outlook for 2026-2035?
• What are the major factors aiding the non alcoholic fatty liver disease (NAFLD) market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major non alcoholic fatty liver disease (NAFLD) market trends?
• Which drug class is expected to dominate the market segment?
• Which route of administration is projected to lead the market segment?
• Which age group is anticipated to drive the market segment?
• Which distribution channel is likely to dominate the market segment?
• Who are the key players involved in the non alcoholic fatty liver disease (NAFLD) market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?